Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Efficacy of anti-myeloma therapies following relapse on idecabtagene vicleucel

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a study evaluating the efficacy of subsequent anti-myeloma therapy in patients with multiple myeloma who relapse after treatment with idecabtagene vicleucel (ide-cel). In this study, 68 patients received different types of treatment after progressing on ide-cel, including corticosteroids, proteasome inhibitors, alkylating agents, immunomodulatory drugs and anti-BCMA therapy. Overall, the time to second disease progression (PFS2) was 13.6 months in patients who received subsequent anti-myeloma treatment and 15.6 months in patients who received anti-BCMA treatment. Overall survival (OS) reached 24.8 months and the overall response to any subsequent treatment was 76% in patients who received subsequent anti-myeloma treatment and 90% in patients who received subsequent anti-BCMA treatment. This data suggests that patients who relapse following treatment with ide-cel still respond to BCMA as a target, and that subsequent anti-myeloma treatments remain effective. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.